Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2010

Open Access 01-12-2010 | Research

Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain

Authors: Joseph R Ghilardi, Katie T Freeman, Juan M Jimenez-Andrade, William G Mantyh, Aaron P Bloom, Michael A Kuskowski, Patrick W Mantyh

Published in: Molecular Pain | Issue 1/2010

Login to get access

Abstract

Pain often accompanies cancer and most current therapies for treating cancer pain have significant unwanted side effects. Targeting nerve growth factor (NGF) or its cognate receptor tropomyosin receptor kinase A (TrkA) has become an attractive target for attenuating chronic pain.
In the present report, we use a mouse model of bone cancer pain and examine whether oral administration of a selective small molecule Trk inhibitor (ARRY-470, which blocks TrkA, TrkB and TrkC kinase activity at low nm concentrations) has a significant effect on cancer-induced pain behaviors, tumor-induced remodeling of sensory nerve fibers, tumor growth and tumor-induced bone remodeling. Early/sustained (initiated day 6 post cancer cell injection), but not late/acute (initiated day 18 post cancer cell injection) administration of ARRY-470 markedly attenuated bone cancer pain and significantly blocked the ectopic sprouting of sensory nerve fibers and the formation of neuroma-like structures in the tumor bearing bone, but did not have a significant effect on tumor growth or bone remodeling.
These data suggest that, like therapies that target the cancer itself, the earlier that the blockade of TrkA occurs, the more effective the control of cancer pain and the tumor-induced remodeling of sensory nerve fibers. Developing targeted therapies that relieve cancer pain without the side effects of current analgesics has the potential to significantly improve the quality of life and functional status of cancer patients.
Appendix
Available only for authorised users
Literature
1.
Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain 1997, 69: 1–18. 10.1016/S0304-3959(96)03267-8PubMedCrossRef
2.
Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80: 1588–94. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-GPubMedCrossRef
3.
Xian CJ, Zhou XF: Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative. Nat Clin Pract Rheumatol 2009, 5: 92–8. 10.1038/ncprheum0982PubMedCrossRef
4.
Balano KB: Anti-inflammatory drugs and myorelaxants. Pharmacology and clinical use in musculoskeletal disease. Prim Care 1996, 23: 329–34.PubMedCrossRef
5.
Feinberg SD: Prescribing analgesics. How to improve function and avoid toxicity when treating chronic pain. Geriatrics 2000, 55: 44. 49–50, 53 passimPubMed
6.
Ivanhoe CB, Hartman ET: Clinical caveats on medical assessment and treatment of pain after TBI. J Head Trauma Rehabil 2004, 19: 29–39. 10.1097/00001199-200401000-00004PubMedCrossRef
7.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ: The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9: 325–38. 10.1038/nrd3003PubMedCrossRef
8.
Opar A: Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010, 9: 257–8. 10.1038/nrd3155PubMedCrossRef
9.
Halvorson KG, Sevcik MA, Ghilardi JR, Sullivan LJ, Koewler NJ, Bauss F, Mantyh PW: Intravenous Ibandronate Rapidly Reduces Pain, Neurochemical Indices of Central Sensitization, Tumor Burden, and Skeletal Destruction in a Mouse Model of Bone Cancer. J Pain Symptom Manage 2008,36(3):289–303. 10.1016/j.jpainsymman.2007.10.005PubMedCentralPubMedCrossRef
10.
Jimenez-Andrade JM, Mantyh WG, Bloom AP, Xu H, Ferng AS, Dussor G, Vanderah TW, Mantyh PW: A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone 2010, 46: 306–13. 10.1016/j.bone.2009.09.013PubMedCentralPubMedCrossRef
11.
Greenfield GQ, MV Boswell, Cole BE: Orthopaedic Pain. Journal/Weiner's pain management: a practical guide for clinicians 2006, 465–76.
12.
Small JR, Scadding JW, Landon DN: A fluorescence study of changes in noradrenergic sympathetic fibres in experimental peripheral nerve neuromas. J Neurol Sci 1990, 100: 98–107. 10.1016/0022-510X(90)90019-JPubMedCrossRef
13.
Lindqvist A, Rivero-Melian C, Turan I, Fried K: Neuropeptide- and tyrosine hydroxylase-immunoreactive nerve fibers in painful Morton's neuromas. Muscle Nerve 2000, 23: 1214–8. 10.1002/1097-4598(200008)23:8<1214::AID-MUS9>3.0.CO;2-APubMedCrossRef
14.
15.
McMahon SB, Bennett DLH, Bevan S, McMahon SB, Koltzenburg M: Inflammatory mediators and modulators of pain. Journal/Wall and Melzack's textbook of pain 2006, xviii. 1239 p
16.
Paterson S, Schmelz M, McGlone F, Turner G, Rukwied R: Facilitated neurotrophin release in sensitized human skin. Eur J Pain 2009, 13: 399–405. 10.1016/j.ejpain.2008.05.005PubMedCrossRef
17.
Pezet S, McMahon SB: Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006, 29: 507–38. 10.1146/annurev.neuro.29.051605.112929PubMedCrossRef
18.
Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV: Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 1995, 7: 1484–1494. 10.1111/j.1460-9568.1995.tb01143.xPubMedCentralPubMedCrossRef
19.
Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM: Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006, 27: 85–91. 10.1016/j.tips.2005.12.001PubMedCrossRef
20.
21.
Malik-Hall M, Dina OA, Levine JD: Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005, 21: 3387–94. 10.1111/j.1460-9568.2005.04173.xPubMedCrossRef
22.
Walsh GS, Krol KM, Kawaja MD: Absence of the p75 neurotrophin receptor alters the pattern of sympathosensory sprouting in the trigeminal ganglia of mice overexpressing nerve growth factor. J Neurosci 1999, 19: 258–73.PubMed
23.
Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Bouhana KS, Trollinger D, Winkler J, Lee P, Andrews SW, Kuskowski MA, Mantyh PW: Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone 2010, in press.
24.
Chao MV: Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4: 299–309. 10.1038/nrn1078PubMedCrossRef
25.
Behnia A, Zhang L, Charles M, Gold MS: Changes in TrkB-like immunoreactivity in rat trigeminal ganglion after tooth injury. J Endod 2003, 29: 135–40. 10.1097/00004770-200302000-00012PubMedCrossRef
26.
Kashiba H, Uchida Y, Senba E: Distribution and colocalization of NGF and GDNF family ligand receptor mRNAs in dorsal root and nodose ganglion neurons of adult rats. Brain Res Mol Brain Res 2003, 110: 52–62. 10.1016/S0169-328X(02)00584-3PubMedCrossRef
27.
Kobayashi K, Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, Noguchi K: Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J Comp Neurol 2005, 493: 596–606. 10.1002/cne.20794PubMedCrossRef
28.
Zhu ZW, Friess H, Wang L, Bogardus T, Korc M, Kleeff J, Buchler MW: Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res 2001, 7: 105–12.PubMed
29.
Kerr BJ, Bradbury EJ, Bennett DL, Trivedi PM, Dassan P, French J, Shelton DB, McMahon SB, Thompson SW: Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J Neurosci 1999, 19: 5138–48.PubMed
30.
Chaudhry V, Giuliani M, Petty BG, Lee D, Seyedsadr M, Hilt D, Cornblath DR: Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000, 23: 189–92. 10.1002/(SICI)1097-4598(200002)23:2<189::AID-MUS7>3.0.CO;2-8PubMedCrossRef
31.
Watanabe M, Endo Y, Kimoto K, Katoh-Semba R, Arakawa Y: Inhibition of adjuvant-induced inflammatory hyperalgesia in rats by local injection of neurotrophin-3. Neurosci Lett 2000, 282: 61–4. 10.1016/S0304-3940(00)00842-9PubMedCrossRef
32.
Mantyh WG, Jimenez-Andrade JM, Stake JI, Bloom AP, Kaczmarska MJ, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW: Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience 2010., 1: 171(2):588–98
33.
Ozawa T, Ohtori S, Inoue G, Aoki Y, Moriya H, Takahashi K: The degenerated lumbar intervertebral disc is innervated primarily by peptide-containing sensory nerve fibers in humans. Spine 2006, 31: 2418–22. 10.1097/01.brs.0000239159.74211.9cPubMedCrossRef
34.
Ozawa T, Aoki Y, Ohtori S, Takahashi K, Chiba T, Ino H, Moriya H: The dorsal portion of the lumbar intervertebral disc is innervated primarily by small peptide-containing dorsal root ganglion neurons in rats. Neurosci Lett 2003, 344: 65–7. 10.1016/S0304-3940(03)00416-6PubMedCrossRef
35.
Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW: Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002, 113: 155–66. 10.1016/S0306-4522(02)00165-3PubMedCrossRef
36.
37.
Ernsberger U: Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res 2009, 336: 349–84. 10.1007/s00441-009-0784-zPubMedCrossRef
38.
McMahon SB, Bennett DLH, Bevan S, Wall PD, McMahon SB, Koltzenburg M: Inflamatory mediators and modulators of pain. Journal/Wall and Melzack's Textbook of Pain 2006, 49–72.CrossRef
39.
Devor M, Wall PD: Type of sensory nerve fibre sprouting to form a neuroma. Nature 1976, 262: 705–8. 10.1038/262705a0PubMedCrossRef
40.
Sung JH, Mastri AR: Aberrant peripheral nerves and microneuromas in otherwise normal medullas. J Neuropathol Exp Neurol 1983, 42: 522–8. 10.1097/00005072-198309000-00004PubMedCrossRef
41.
Madduri S, Papaloizos M, Gander B: Synergistic effect of GDNF and NGF on axonal branching and elongation in vitro. Neurosci Res 2009, 65: 88–97. 10.1016/j.neures.2009.06.003PubMedCrossRef
42.
Kryger GS, Kryger Z, Zhang F, Shelton DL, Lineaweaver WC, Buncke HJ: Nerve growth factor inhibition prevents traumatic neuroma formation in the rat. J Hand Surg Am 2001, 26: 635–44. 10.1053/jhsu.2001.26035PubMedCrossRef
43.
Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG: Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008, 64: 644–53. 10.1002/ana.21527PubMedCrossRef
44.
Devor M, Keller CH, Ellisman MH: Spontaneous discharge of afferents in a neuroma reflects original receptor tuning. Brain Res 1990, 517: 245–250. 10.1016/0006-8993(90)91033-DPubMedCrossRef
45.
Devor M, Govrin-Lippmann R: Axoplasmic transport block reduces ectopic impulse generation in injured peripheral nerves. Pain 1983, 16: 73–85. 10.1016/0304-3959(83)90087-8PubMedCrossRef
46.
Devor M, Govrin-Lippmann R, Angelides K: Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993, 13: 1976–92.PubMed
47.
Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, Muller MW, Giese T, Buchler MW, Giese NA, Friess H: Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases. Gastroenterology 2009, 136: 177–186 e1. 10.1053/j.gastro.2008.09.029PubMedCrossRef
48.
Winkler J: Analgesic effects of a potent and selective kinase inhibitor of neurotrophin receptors TrkA, TrkB, and TrkC. Journal/8th IASP Research Symposium 2009.
49.
Bouhana KS, Impastato R, Jiang Y, Wallace RD, Hartley DP, Do MG, von Carlowitz I: Analgesic effects of a potent and selective kinase inhibitor of neurotrophin receptors TrkA, TrkB, and TrkC in a model of inflammatory pain. Journal/Keystone Symposium- Neurobiology of Pain 2008, in press.
Metadata
Title
Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain
Authors
Joseph R Ghilardi
Katie T Freeman
Juan M Jimenez-Andrade
William G Mantyh
Aaron P Bloom
Michael A Kuskowski
Patrick W Mantyh
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2010
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-6-87

Other articles of this Issue 1/2010

Molecular Pain 1/2010 Go to the issue

Research

Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurones

Research

Blocking spinal CCR2 with AZ889 reversed hyperalgesia in a model of neuropathic pain

Research

Combining ketamine with astrocytic inhibitor as a potential analgesic strategy for neuropathic pain. ketamine, astrocytic inhibitor and pain

Research

Analgesic effect of highly reversible ω-conotoxin FVIA on N-type Ca2+ channels

Research

Long lasting pain hypersensitivity following ligation of the tendon of the masseter muscle in rats: A model of myogenic orofacial pain

Research

A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism